Previous 10 | Next 10 |
THE MULTI-TARGET RESEARCH AND DEVELOPMENT PARTNERSHIP WILL FOCUS ON SEVERE SKIN DISEASES, INCLUDING IMMUNE-MEDIATED INFLAMMATORY CONDITIONS SUCH AS ATOPIC DERMATITIS AND NON-MELANOMA SKIN CANCER SUCH AS BASAL CELL CARCINOMA THE COLLABORATION LEVERAGES EVOTEC'S DATA-DRIVEN EVO IR&a...
Partnership Leverages Sernova’s Proprietary Cell Pouch System™ with Evotec’s iPSC-Based Insulin-Producing Beta Cells Partners to Develop and Commercialize an Off-The-Shelf Cell Replacement Therapy for Treatment of Patients with Insulin-Dependent Diabetes ...
Germany-based Evotec (NASDAQ:EVO) (OTCPK:EVOTF) and Canada's Sernova (OTCQB:SEOVF) are collaborating to develop a therapy for diabetes. The companies plan to develop an implantable iPSC-based beta cell replacement therapy to treat insulin-dependent diabetes, including type 1 and 2. Under...
The ADRs of Evotec SE (NASDAQ:EVO) (OTCPK:EVOTF) have surged in the pre-market Tuesday after the German biotech announced an eight-year extension for its partnership with Bristol Myers Squibb (BMY) in targeted protein degradation. Per the terms, the parties will make full use of Evotec’...
HAMBURG, GERMANY / ACCESSWIRE / May 10, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces today that the Company has extended and expanded its partnership with Bristol Myers Squibb (BMY) in targeted protein degradation, ori...
8-YEAR EXTENSION AND EXPANSION OF COLLABORATION TO DEVELOP PIPELINE OF MOLECULAR GLUE DEGRADERS COLLABORATION LEVERAGES EVOTEC'S PROPRIETARY EVO PANOMICS AND EVO PANHUNTER PLATFORMS COVERING HIGH-PERFORMANCE MULTI-OMICS AND INTEGRATED AI/ML-SUPPORTED DATA ANALYTICS $ 2...
HAMBURG, GERMANY / ACCESSWIRE / May 4, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first quarter of 2022 on Wednesday, 11 May 2022. The Company is going to hold a conference call to discuss the res...
Evotec SE (EVO) Q4 2021 Earnings Conference Call April 12, 2022 08:00 ET Company Participants Werner Lanthaler - Chairman and Chief Executive Officer Cord Dohrmann - Chief Scientific Officer Craig Johnstone - Chief Operating Officer Enno Spillner - Chief Financial Officer Conference Call Part...
STRONG FINANCIAL RESULTS: 23% INCREASE IN GROUP REVENUES SIGNIFICANTLY EXCEEDING GUIDANCE DATA-DRIVEN PLATFORMS AND TECHNOLOGIES INCREASE PROBABILITIES OF SUCCESS IN ALL MODALITIES SUBSTANTIALLY STRENGTHENED BALANCE SHEET PROVIDING VERY GOOD FOUNDATION AND LEVERAGE FOR SUSTAINABLE...
THE PROGRAMME DESIGNATION IS BASED ON AN ANTISENSE-BASED APPROACH WHICH TRIGGERS A US$ 16 M PAYMENT TO EVOTEC BY BRISTOL MYERS SQUIBB EVOTEC SOURCES LNAPLUS(TM) ANTISENSE TECHNOLOGY THROUGH A STRATEGIC PARTNERSHIP WITH SECARNA PHARMACEUTICALS HAMBURG, GERMANY / ACCESSWIRE / Apri...
News, Short Squeeze, Breakout and More Instantly...
Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases HAMBURG, GERMANY / ACCESSWIRE / July 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(NASDAQ:EVO) (MDAX/TecDAX , ISIN: DE0005664809) today announced it has entered into a mul...
Just - Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars Additional biosimilars potentially to be added to Sandoz development pipeline Further guarantees for Sandoz long-term commercial supply security HAMBURG, GERMANY...
Just - Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DOD's Manufacturing Optimization Program Manufacturing solution includes seamless integration of accelerated mAb drug development into the overall Manufacturing Optimiz...